SCHEMBL200400

SCHEMBL200400

CCCCCCCCCCCCCC(=O)OCC[N+](C)(C)C

nearest known ligand 0.74

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DGKA P23743 1/20 0.74
ADRA2A P08913 1/20 0.67
ADRA1A P35348 1/20 0.67
MAPT P10636 3/20 0.64
BLM P54132 1/20 0.64
DNM1 Q05193 1/20 0.61
ACHE P22303 3/20 0.58
RAD52 P43351 1/20 0.58
NPSR1 Q6W5P4 1/20 0.58
PAM P19021 2/20 0.56
FABP3 P05413 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.54
NR5A2 O00482 1/20 0.54
NR5A1 Q13285 1/20 0.54
TSHR P16473 1/20 0.53
PRSS1 P07477 1/20 0.53
PRSS2 P07478 1/20 0.53
PRSS3 P35030 1/20 0.53
NAAA Q02083 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL200767 1.00 DGKA (0.74) DGKAADRA2AADRA1AMAPTBLM
SCHEMBL198091 1.00 DGKA (0.74) DGKAADRA2AADRA1AMAPTBLM
SCHEMBL8385105 1.00 DGKA (0.74) DGKAADRA2AADRA1AMAPTBLM
SCHEMBL8383254 1.00 DGKA (0.74) DGKAADRA2AADRA1AMAPTBLM
SCHEMBL153530 1.00 DGKA (0.74) DGKAADRA2AADRA1AMAPTBLM
SCHEMBL8385120 1.00 DGKA (0.74) DGKAADRA2AADRA1AMAPTBLM
SCHEMBL8385098 1.00 DGKA (0.74) DGKAADRA2AADRA1AMAPTBLM
SCHEMBL6829812 1.00 DGKA (0.74) DGKAADRA2AADRA1AMAPTBLM
SCHEMBL8855865 1.00 DGKA (0.74) DGKAADRA2AADRA1AMAPTBLM
SCHEMBL8382713 1.00 DGKA (0.74) DGKAADRA2AADRA1AMAPTBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260115140-A1 COMPOSITIONS FOR ENHANCED MUCOSAL PENETRATION SHIN NIPPON BIOMEDICAL LABORATORIES LTD (JP) 2026-04-30 US claimed
EP-4719476-A1 COMPOSITIONS FOR ENHANCED MUCOSAL PENETRATION Shin Nippon Biomedical Laboratories, Ltd. (JP) 2026-04-08 EP claimed
WO-2024246607-A1 COMPOSITIONS FOR ENHANCED MUCOSAL PENETRATION SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) 2024-12-05 WO claimed
WO-2024196902-A2 COUPLING OPTICAL AND POTENTIOMETRIC MEASUREMENTS WITH MAGNETIC LEVITATION WHITESIDES GEORGE M (US) 2024-09-26 WO claimed
WO-2024196901-A2 A HIGH THROUGHPUT ION-SENSING METHOD WHITESIDES GEORGE M (US) 2024-09-26 WO claimed
CN-118655308-A Method for detecting organic phosphorus by liquid crystal double-emulsion controlled-release combined pregnancy test strip 临沂大学 2024-09-17 CN claimed
EP-4226918-A1 PHARMACEUTICAL SINGLE DOSAGE FORM FOR ORAL DELIVERY OF PEPTIDES Majewski, Filip (PL) 2023-08-16 EP claimed
CN-109158083-B Preparation method and application of biomass-based carbon material 西北师范大学 2021-04-13 CN claimed
CN-109158083-A A kind of preparation method and its usage of biomass-based carbon material 西北师范大学 2019-01-08 CN claimed
CN-105241882-B Application of the Liquid Crystal Sensor in detection organophosphorus pesticide and carbamate chemicals for agriculture 山东大学 2017-10-27 CN claimed
EP-0206947-B1 PHARMACEUTICAL COMPOSITION CONTAINING CHOLINE ESTER SALTS FOR ENHANCING GASTROINTESTINAL TRACT ABSORPTION MERCK & CO. INC. (US) 1992-04-15 EP claimed
EP-0214898-B1 CHOLINE ESTERS AS ABSORPTION-ENHANCING AGENTS FOR DRUG DELIVERY THROUGH MUCOUS MEMBRANES OF THE NASAL, BUCCAL, SUBLINGUAL AND VAGINAL CAVITIES MERCK & CO. INC. (US) 1992-03-11 EP claimed
US-4973579-A VIRICIDES MERCK & CO., INC. (US) 1990-11-27 US claimed
US-4963556-A ANTIVIRAL AGENTS MERCK & CO., INC. (US) 1990-10-16 US claimed
US-4835138-A Choline esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities MERCK & CO., INC. (US) 1989-05-30 US claimed
US-4822773-A Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts MERCK & CO., INC. (US) 1989-04-18 US claimed
US-4729989-A Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts MERCK & CO., INC. (US) 1988-03-08 US claimed
US-4692441-A B-LACTAM ANTIBIOTICS MERCK & CO., INC. (US) 1987-09-08 US claimed
EP-0214898-A2 Choline esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities MERCK & CO. INC. (US) 1987-03-18 EP claimed
EP-0206947-A2 Pharmaceutical composition containing choline ester salts for enhancing gastrointestinal tract absorption MERCK & CO. INC. (US) 1986-12-30 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260115140-A1 COMPOSITIONS FOR ENHANCED MUCOSAL PENETRATION SLC10A2, SLC5A7, SLC18A3 DGKA 3663/4885ADRA2A 619/4885ADRA1A 526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.